EDGAR Filing Documents for 0001193125-21-120391

Form 8-K - Current report:

SEC Accession No. 0001193125-21-120391

Filing Date

2021-04-19

Accepted

2021-04-19 07:51:03

Documents

Period of Report

2021-04-16

Items

Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	FORM 8-K	d135127d8k.htm iXBRL	8-K	27780
2	EX-10.1	d135127dex101.htm	EX-10.1	20010
	Complete submission text file	0001193125-21-120391.txt		179432

Data Files

Seq	Description	Document	Type	Size
3	XBRL TAXONOMY EXTENSION SCHEMA	galt-20210416.xsd	EX-101.SCH	3093
4	XBRL TAXONOMY EXTENSION LABEL LINKBASE	galt-20210416_lab.xml	EX-101.LAB	18138
5	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	galt-20210416_pre.xml	EX-101.PRE	11423
6	EXTRACTED XBRL INSTANCE DOCUMENT	d135127d8k_htm.xml	XML	3471

Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071

Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186

GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)